Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322473 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study, sponsored by MoonLake Immunotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT05322473 is a Phase 2 study that has completed, run by MoonLake Immunotherapeutics. The registered enrollment target is 234 participants.
The verdict
NCT05322473, a Phase 2 study, has completed, sponsored by MoonLake Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Interventions
- OTHER Placebo
- DRUG Adalimumab
- DRUG Sonelokimab (M1095)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2022-04-25 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05322473
The ClinicalTrials.gov registry entry for NCT05322473 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MoonLake Immunotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05322473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05322473 about?
NCT05322473 is a clinical study titled "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
What is the current status of trial NCT05322473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2022-04-25. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT05322473?
The interventions under investigation include: Placebo (OTHER), Adalimumab (DRUG), Sonelokimab (M1095) (DRUG).
Who is sponsoring clinical trial NCT05322473?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.